Coronavirus Update - 07th August 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual and have started welcoming limited numbers of visitors to site

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

The latest news from Arcinova

Mark joins Arcinova from AIM-listed Physiomics plc, where he was CEO for 5 years. Mark’s previous roles include CEO of Envirogene and VP of Business Development at Excelsyn. Before joining Excelsyn, Mark spent 10 years in Cambridge from startup company (Cambridge Genetics Limited) through two mergers to become Director of Commercial Operations at BioFocus, a drug discovery services provider which was subsequently acquired by Galapagos. Mark holds a degree in Genetics from the University of Nottingham, a PhD in Molecular Biology from the University of Newcastle and an MBA from Imperial College London. 

Ian Shott, Arcinova Managing Director, commented "I've known Mark for many years and watched his career develop and I am delighted he is now joining us in this critical role".  

Mark Chadwick added "I am extremely enthusiastic to be joining the Arcinova team. The facilities are second-to-none with great potential to develop the business".

MarkChadwick

 

 




Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.

GET IN TOUCH